Evidence map›Paper›PMID 38883731›Full record

ArticlemedRxiv : the preprint server for health sciences2024

ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.

Stephanie Guillet, Tomi Lazarov, Natasha Jordan, Bertrand Boisson, Maria Tello, Barbara Craddock, Ting Zhou, Chihiro Nishi, Rohan Bareja, Hairu Yang and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Stephanie GuilletImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Tomi LazarovImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.ORCID 0000-0002-6312-0080
Natasha JordanCentre for Molecular and Cellular Biology of Inflammation (CMCBI), King's College London and Louise Coote Lupus Unit, Guy's and Thomas' Hospitals, London SE1 1UL, UK.
Bertrand BoissonSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, 10065 NY, USA.
Maria TelloImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Barbara CraddockDepartment of Physiology and Biophysics, Stony Brook University School of Medicine, Stony Brook, NY, 11794-8661.
Ting ZhouSKI Stem Cell Research Core, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Chihiro NishiLaboratory of Biochemistry & Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871.
Rohan BarejaCary and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Meyer Cancer Center Weill Cornell Medical College, New York, New York 10065, USA.
Hairu YangImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Frederic Rieux-LaucatUniversity of Paris Cité, Imagine Institute, Paris, France.ORCID 0000-0001-7858-7866
Rosa Irene Fregel LorenzoUniversity of La Laguna, San Cristóbal de La Laguna, Santa Cruz de Tenerife - Spain (38200).ORCID 0000-0002-2951-6508
Sabrina D DyallDepartment of Biosciences and Ocean Studies, Faculty of Science, University of Mauritius, Reduit, Mauritius.
David IsenbergCentre for Rheumatology, Division of Medicine, University College London, The Rayne Building, University College London.
David D'CruzCentre for Molecular and Cellular Biology of Inflammation (CMCBI), King's College London and Louise Coote Lupus Unit, Guy's and Thomas' Hospitals, London SE1 1UL, UK.
Nico LachmannInstitute of Experimental Hematology, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover 30625, Germany.
Olivier ElementoCary and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Meyer Cancer Center Weill Cornell Medical College, New York, New York 10065, USA.
Agnes VialeMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Nicholas D SocciMarie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Laurent AbelSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, 10065 NY, USA.
Shigekazu NagataLaboratory of Biochemistry & Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871.ORCID 0000-0001-9758-8426
Morgan HuseImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
W Todd MillerDepartment of Physiology and Biophysics, Stony Brook University School of Medicine, Stony Brook, NY, 11794-8661.
Jean-Laurent CasanovaSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, 10065 NY, USA.
Frederic GeissmannImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.ORCID 0000-0001-5029-2468

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Human genetics of TB resistance in HIV-infected personsR01AI124349 · NIAID · MCGILL UNIVERSITY HEALTH CTR RES INST · PI SCHURR, ERWIN · 2016 to 2020
$8.0M
Synaptic Control of Cytotoxic T cell FunctionR01AI087644 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HUSE, MORGAN A · 2010 to 2025
$7.3M
Macrophage development and specification in mice.R01AI130345 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Frederic Geissmann · 2017 to 2026
$5.7M
SUSTRATE SPECIFICITY OF NONRECEPTOR TYROSINE KINASER01CA058530 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI MILLER, W TODD · 1999 to 2018
$3.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA058530NIAID NIH HHS R01 AI087644NIAID NIH HHS R01 AI124349NIAID NIH HHS R01 AI130345
6 · The paper itself

Abstract

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with systemic lupus erythematosus (SLE) we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies

Identifiers

PMID38883731
PMCPMC11177913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.